For a small research organization like LIDDS, cooperation is a vital part of our operational model (way-of-working). The agile and efficient development of the company is dependent on external collaborations such as with academia, licensing partners, Contract Research Organizations (CROs), and Contract Manufacturing Organizations (CMOs).
External collaboration agreements
- In 2021, LIDDS signed a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. The scope of the program is to develop oncology products based on the NanoZolid technology for a non-disclosed indication.
- In 2018, LIDDS entered into an exclusive license agreement with Jianxi Puheng Pharma. The agreement only applies to China and to Liproca Depot for the treatment of prostate cancer. License revenues include milestone payments and royalties on sales. According to the agreement, Jianxi Puheng Pharma will finance the upcoming Phase III study in China.
- In 2017, LIDDS signed a research and development agreement with Belina AB. The scope of the work was development of a NanoZolid-formulated drug for treatment of patients with breast cancer. The agreement includes a feasibility program and an exclusive option for a global license agreement.
- In 2017, LIDDS signed a research and development agreement with a non-disclosed global pharmaceutical company. The agreement included a feasibility program and an exclusive option for a global license agreement.
- In 2021, LIDDS and PharmIdea entered into a manufacturing agreement including the manufacturing of new product candidates e.g. biomolecules and cytostatic drugs. The manufacturing of the NanoZolid formulated TLR9 is the first project within this collaboration.
- In 2015, LIDDS and Recipharm entered into an exclusive collaboration agreement regarding the production process and commercial manufacturing of Liproca Depot for treatment of prostate cancer.